Enara Bio
Generated by Meeveem AI
"Pioneering Dark Antigen discovery to advance cancer immunotherapy for solid tumours"
Oxford
•51 - 250 Employees
•Biotechnology
About Enara Bio
Enara Bio discovers and develops cancer immunotherapies by targeting Dark Antigens, a novel class of cancer-specific markers from previously unexplored regions of the genome. Using proprietary platforms, the company identifies these hidden antigens and engineers bispecific T-cell engagers that redirect immune cells to destroy tumours. The lead program, ENA101, targets a newly discovered antigen called DARKFOX. The work unlocks genomic information once considered unusable, creating treatment options for patients with solid cancers who lack effective therapies. Collaborating with pharmaceutical partners and research institutions, Enara Bio validates targets and accelerates development to deliver treatments for broad patient populations.
68
Team Members
2016
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A world where genomic dark matter is fully illuminated, revealing novel cancer targets that enable transformative immunotherapies to eliminate solid tumours and free patients from the burden of disease.
Our Mission
At Enara Bio, our mission is to exploit previously uncharted genomic dark matter to develop cancer immunotherapies that deliver transformative benefit for broad patient populations.